Skip to main content

Table 1 Participant characteristics summary table by neuropathologic grouping

From: Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

 

PSP (n = 2)

AD (n = 9)

AGD (n = 2a)

PART (n = 14)

PA (n = 7)

Age at plasma, years

80 (79,81)

87 (84,90)

89 (88,89)

81 (78,84)

79 (72,86)

Age at death, years

82 (81,83)

89 (86,92)

90 (90,91)

83 (81,86)

80 (74,88)

Postmortem interval, hours

4 (4,5)

13 (9,18)

20 (19,21)

20 (18,22)

14 (11,21)

Females

0 (0%)

4 (44%)

1 (50%)

8 (57%)

2 (29%)

APOE ε4 positivity

0 (0%)

4 (44%)

1 (50%)

2 (14%)

3 (43%)

Clinical Dementia Rating, 0–18

0.5 (0,1)

4 (0.5,7)

2 (1,3)

0 (0,0)

0 (0,0.5)

Mini-Mental State Examination, 0–30

29 (28,30)

23 (23,27)

28 (27,28)

28 (28,29)

28 (28,30)

Tau-PET parietal SUVr

n/a

1.2 (1.1,1.3)

n/a

1.0 (1.0,1.1)

1.1 (1.1,1.1)

Fluid levels

 MSD plasma p-tau181, pg/mL

1.6 (1.3,1.9)

3.4 (2.5,4.3)

1.7 (1.6,1.9)

1.2 (0.9,1.5)

1.3 (1.1,1.8)

 MSD plasma p-tau217, pg/mL

0.25 (0.21,0.29)

0.69 (0.52,0.75)

0.18 (0.17,0.20)

0.15 (0.12,0.20)

0.19 (0.17,0.29)

 Creatinine, mg/dL

1.0 (1.0,1.0)

1.2 (0.9,1.3)

1.4 (1.2,1.6)

1.0 (1.0,1.4)

1.1 (1.1,1.3)

 ALT level, U/L

n/a

22 (15,24)

21 (21,21)

21 (18,27)

19 (18,47)

 AST level, U/L

24 (21,27)

23 (19,29)

18 (15,20)

26 (23,31)

28 (22,49)

Global scales

 Braak stage, 0-VI

III (III, III)

IV (IV, V)

II (II, II)

II (II, III)

II (II, II)

 0 | I | II | III | IV | V | VI, counts

0|0|0|2|0|0|0

0|0|0|0|5|3|1

0|0|2|0|0|0|0

1|3|4|5|1|0|0

0|2|4|1|0|0|0

 Thal phase, 0–5

3 (3,3)

5 (4,5)

0.5 (0,1)

1 (1,2)

3 (3,4)

 0 | 1 | 2 | 3 | 4 | 5, counts

0|0|0|2|0|0

0|0|0|2|2|5

1|1|0|0|0|0

3|6|5|0|0|0

0|0|0|4|3|0

 Diffuse plaques, Moderate-Frequent

2 (100%)

9 (100%)

1 (50%)

3 (21%)

7 (100%)

 Neuritic plaques, Moderate-Frequent

2 (100%)

9 (100%)

0 (0%)

1 (7%)

4 (57%)

 LATE-NC stage, 0–3

0 (0,0)

1 (0,2)

1 (1,2)

0 (0,0)

0 (0,0)

 Kalaria CVD score, 0–10

3 (3,3)

4 (3,5)

6 (5,6)

2 (2,4)

3 (2,5)

Regional measures

 Parietal pT181, %

0.27 (0.27,0.27)

0.64 (0.54,0.93)

0.27 (0.22,0.32)

0.17 (0.12,0.22)

0.11 (0.080,0.23)

 Parietal pT217, %

0.46 (0.38,0.55)

0.63 (0.38,4.9)

0.22 (0.20,0.25)

0.080 (0.060,0.090)

0.11 (0.10,0.12)

 Parietal amyloid-β, %

2.7 (2.5,3.0)

2.7 (2.0,4.6)

0.24 (0.16,0.32)

0.16 (0.10,0.46)

1.1 (0.43,1.5)

 Hippocampal pT181, %

0.58 (0.41,0.74)

2.5 (1.9,3.9)

0.84 (0.51,1.2)

0.28 (0.18,0.34)

0.34 (0.16,0.38)

 Hippocampal pT217, %

4.8 (3.0,6.6)

21 (10,28)

6.6 (3.5,9.7)

2.3 (0.34,3.7)

0.95 (0.67,2.7)

 Hippocampal amyloid-β, %

0.36 (0.25,0.47)

0.64 (0.16,1.8)

0.050 (0.040,0.050)

0.050 (0.040,0.12)

0.11 (0.060,0.34)

 LC neurons/mm2

25 (18,33)

30 (22,33)

22 (22,22)

44 (38,52)

45 (39,52)

 nbM neurons/mm2

14 (11,17)

19 (14,19)

30 (26,35)

22 (17,27)

20 (15,29)

  1. Data presented are median and interquartile range (25th,75th). aAGD case with high creatinine was not included. Acronyms: AD Alzheimer’s disease, AGD Argyrophilic grains disease, ALT Alanine transaminase, AST Aspartate aminotransferase, CVD Cerebrovascular disease, CAA Cerebral amyloid angiopathy, LATE-NC Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change, LC Locus coeruleus, MSD Meso scale discovery. p-tau phosphorylated tau in plasma, n/a not available, nbM nucleus basalis of Meynert, PA Pathological aging, PART Primary age-related tauopathy, PSP Progressive supranuclear palsy, pT phosphorylated threonine for immunohistochemical measures of tau
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326